This site is intended for healthcare professionals

Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Pathophysiology

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

  • over 90% of patients have TSH receptor antibodies which stimulate the thyroid cell - these are known as thyroid stimulating immunoglobulins or TSI, and correlate with the degree of hyperthyroidism

  • a second set of TSH receptor antibodies stimulate thyroid growth - but not hormone production. These thyroid growth-stimulating immunoglobulins (TGI's) determine the degree of thyroid enlargement, if any. TGI's may occur also in other toxic and non-toxic goitre

  • eye involvement may be the result of an independent ophthalmic immunoglobulin against the eye muscle basement cell membrane. Ophthalmic Graves' disease may exhibit all the features of Graves' ophthalmopathy yet the patient is euthyroid. Alternatively, autoantibody against the TSH receptor on retrobulbar fibroblasts may be the source of ophthalmic manifestations

  • in some cases patients with Graves' disease produce antithyroid peroxidase (previously known as antimicrosomal antibodies) in addition to TSI, and about 5% of patients will become hypothyroid spontaneously with time

  • the clinical spectrum of Graves' disease is made more complex by the rare occurrence of patients who secrete antibodies that either lead to stimulation of the TSH receptor (TSI) or result in the blocking of the TSH receptor. Therefore, depending on the activity of the stimulating and blocking antibodies the clinical condition ranges from hyperthyroidism to euthyroidism, to hypothyroidism and recurrent hyperthyroidism

Create an account to add page annotations

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.